RU2002113659A - Способ и композиции для перорального введения таксанов больным людям - Google Patents

Способ и композиции для перорального введения таксанов больным людям Download PDF

Info

Publication number
RU2002113659A
RU2002113659A RU2002113659/15A RU2002113659A RU2002113659A RU 2002113659 A RU2002113659 A RU 2002113659A RU 2002113659/15 A RU2002113659/15 A RU 2002113659/15A RU 2002113659 A RU2002113659 A RU 2002113659A RU 2002113659 A RU2002113659 A RU 2002113659A
Authority
RU
Russia
Prior art keywords
taxane
docetaxel
paclitaxel
specified
formulation
Prior art date
Application number
RU2002113659/15A
Other languages
English (en)
Russian (ru)
Inventor
Сэмюэл БРОДОР (US)
Сэмюэл БРОДОР
Кеннет ДАЧИН (US)
Кеннет ДАЧИН
Сами СЕЛИМ (US)
Сами СЕЛИМ
Original Assignee
Бейкер Нортон Фармасьютикалз, Инк. (Us)
Бейкер Нортон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейкер Нортон Фармасьютикалз, Инк. (Us), Бейкер Нортон Фармасьютикалз, Инк. filed Critical Бейкер Нортон Фармасьютикалз, Инк. (Us)
Publication of RU2002113659A publication Critical patent/RU2002113659A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2002113659/15A 1999-10-27 2000-10-27 Способ и композиции для перорального введения таксанов больным людям RU2002113659A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27
US60/162,310 1999-10-27

Publications (1)

Publication Number Publication Date
RU2002113659A true RU2002113659A (ru) 2004-01-27

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002113659/15A RU2002113659A (ru) 1999-10-27 2000-10-27 Способ и композиции для перорального введения таксанов больным людям

Country Status (18)

Country Link
EP (1) EP1225956A1 (ko)
JP (1) JP2003512443A (ko)
KR (1) KR20030019296A (ko)
CN (1) CN1450923A (ko)
AU (1) AU1104201A (ko)
BR (1) BR0015149A (ko)
CA (1) CA2389583A1 (ko)
CO (1) CO5251425A1 (ko)
CZ (1) CZ20021484A3 (ko)
HU (1) HUP0203303A3 (ko)
IL (1) IL149360A0 (ko)
MX (1) MXPA02004164A (ko)
NO (1) NO20022008L (ko)
PL (1) PL354777A1 (ko)
RU (1) RU2002113659A (ko)
SK (1) SK5822002A3 (ko)
WO (1) WO2001030448A1 (ko)
ZA (1) ZA200203358B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
EP1337273A2 (en) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CA2504268A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
US9402812B2 (en) 2009-09-23 2016-08-02 Indu JAVERI Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
IL305727A (en) * 2021-03-17 2023-11-01 Dompe Farm Spa C5AR1 inhibitors to treat a hypersensitivity reaction to TAXANES
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
CN1550231A (zh) * 1997-05-27 2004-12-01 �Ϳˡ�ŵ��ҩ�����޹�˾ 给予病人口服紫杉烷类药物的方法和组合物
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
JP4695260B2 (ja) * 1998-04-01 2011-06-08 オバン・エナジー・リミテッド 抗癌組成物
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
KR20030019296A (ko) 2003-03-06
WO2001030448A1 (en) 2001-05-03
IL149360A0 (en) 2002-11-10
SK5822002A3 (en) 2003-01-09
CA2389583A1 (en) 2001-05-03
CZ20021484A3 (cs) 2003-12-17
JP2003512443A (ja) 2003-04-02
AU1104201A (en) 2001-05-08
NO20022008D0 (no) 2002-04-26
EP1225956A1 (en) 2002-07-31
CO5251425A1 (es) 2003-02-28
HUP0203303A2 (hu) 2003-02-28
ZA200203358B (en) 2003-04-29
PL354777A1 (en) 2004-02-23
BR0015149A (pt) 2002-10-29
HUP0203303A3 (en) 2005-01-28
MXPA02004164A (es) 2002-10-17
NO20022008L (no) 2002-06-19
CN1450923A (zh) 2003-10-22

Similar Documents

Publication Publication Date Title
RU2002113659A (ru) Способ и композиции для перорального введения таксанов больным людям
CN1133460C (zh) 大环内酯或环孢菌素与聚乙氧基化饱和羟基脂肪酸的药物组合物
EP0876143B1 (en) Tumor necrosis factor alpha (tnf-alpha) inhibiting pharmaceuticals
RU2018121314A (ru) Применение производного рапамицина
JP2003519659A5 (ko)
JP2012529486A5 (ko)
RU2002121507A (ru) Композиция фульвестранта
JP2005515966A5 (ko)
RU97112888A (ru) Способ, композиции и наборы для повышения пероральной биологической доступности фармацевтических агентов
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP2015007096A (ja) 運動障害の予防および／または治療剤
RU2003100507A (ru) Фармацевтические композиции
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JPH1036260A (ja) 抗ガン剤の効力増強方法
CA2290446A1 (en) Method and compositions for administering taxanes orally to human patients
JPH0430924B2 (ko)
NO20001828L (no) Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus
CA2521182A1 (en) Composition for improving cognition and memory
RU2004134573A (ru) Фармацевтическая композиция, включающая ингибитор липазы и глюкоманнан
CN1226175A (zh) 吸收促进剂
RU2016110546A (ru) Комбинированная лекарственная терапия
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
JP2010509389A (ja) 化学療法剤により誘起された末梢神経毒性の処置に有効なピロロ［１，２−ａ］イミダゾールジオン

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20050527